118 related articles for article (PubMed ID: 25385733)
1. Neoadjuvant phase II studies of modified methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer.
Adesunloye BA
J Clin Oncol; 2014 Dec; 32(36):4170. PubMed ID: 25385733
[No Abstract] [Full Text] [Related]
2. Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy in bladder cancer: ready for prime time?
Pouessel D; Gauthier H; Serrate C; Pfister C; Culine S
J Clin Oncol; 2014 Dec; 32(36):4168-9. PubMed ID: 25385728
[No Abstract] [Full Text] [Related]
3. Neoadjuvant chemotherapy for muscle-invasive bladder cancer: are we asking the right questions?
Aragon-Ching JB
J Clin Oncol; 2014 Dec; 32(36):4169-70. PubMed ID: 25385734
[No Abstract] [Full Text] [Related]
4. Everything old is new again! Neoadjuvant chemotherapy in the treatment of muscle-invasive bladder cancer.
Sternberg CN; Apolo AB
J Clin Oncol; 2014 Jun; 32(18):1868-70. PubMed ID: 24821880
[No Abstract] [Full Text] [Related]
5. Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye.
Plimack ER; Hoffman-Censits J; Rosenberg JE; Wong YN; Bellmunt J; Choueiri TK
J Clin Oncol; 2014 Dec; 32(36):4171-2. PubMed ID: 25385730
[No Abstract] [Full Text] [Related]
6. Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye.
Sternberg CN; Apolo AB
J Clin Oncol; 2014 Dec; 32(36):4172-3. PubMed ID: 25385726
[No Abstract] [Full Text] [Related]
7. Bladder cancer: accelerating MVAC.
Killock D
Nat Rev Clin Oncol; 2014 Jul; 11(7):378. PubMed ID: 24863165
[No Abstract] [Full Text] [Related]
8. Bladder cancer: Accelerating MVAC.
Killock D
Nat Rev Urol; 2014 Jun; 11(6):307. PubMed ID: 24861327
[No Abstract] [Full Text] [Related]
9. Re: Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.
Chang SS
J Urol; 2015 Jun; 193(6):1932. PubMed ID: 25986790
[No Abstract] [Full Text] [Related]
10. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.
Plimack ER; Hoffman-Censits JH; Viterbo R; Trabulsi EJ; Ross EA; Greenberg RE; Chen DY; Lallas CD; Wong YN; Lin J; Kutikov A; Dotan E; Brennan TA; Palma N; Dulaimi E; Mehrazin R; Boorjian SA; Kelly WK; Uzzo RG; Hudes GR
J Clin Oncol; 2014 Jun; 32(18):1895-901. PubMed ID: 24821881
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.
Choueiri TK; Jacobus S; Bellmunt J; Qu A; Appleman LJ; Tretter C; Bubley GJ; Stack EC; Signoretti S; Walsh M; Steele G; Hirsch M; Sweeney CJ; Taplin ME; Kibel AS; Krajewski KM; Kantoff PW; Ross RW; Rosenberg JE
J Clin Oncol; 2014 Jun; 32(18):1889-94. PubMed ID: 24821883
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy in transitional-cell carcinoma of the bladder.
McLaren DB
Clin Oncol (R Coll Radiol); 2005 Oct; 17(7):503-7. PubMed ID: 16238137
[TBL] [Abstract][Full Text] [Related]
13. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.
Lancet; 1999 Aug; 354(9178):533-40. PubMed ID: 10470696
[TBL] [Abstract][Full Text] [Related]
15. Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma.
Viens P; Gravis G; Bladou F; Lechevallier E; Baume D; Camerlo J; Cowen D; Coulange C; Serment G; Resbeut M; Maraninchi D
Eur Cytokine Netw; 1996 Sep; 7(3):395-9. PubMed ID: 8954183
[TBL] [Abstract][Full Text] [Related]
16. Absence of immunohistochemical metallothionein staining in bladder tumor specimens predicts response to neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy.
Bahnson RR; Becich M; Ernstoff MS; Sandlow J; Cohen MB; Williams RD
J Urol; 1994 Dec; 152(6 Pt 2):2272-5. PubMed ID: 7966723
[TBL] [Abstract][Full Text] [Related]
17. Is Bcl-2 a predictive marker of neoadjuvant chemotherapy response in patients with urothelial bladder cancer undergoing radical cystectomy?
Turker P; Segersten U; Malmström PU; Hemdan T
Scand J Urol; 2019 Feb; 53(1):45-50. PubMed ID: 30806186
[No Abstract] [Full Text] [Related]
18. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
[TBL] [Abstract][Full Text] [Related]
19. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N
J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282
[TBL] [Abstract][Full Text] [Related]
20. Bladder-sparing approach in the treatment of invasive bladder cancer.
Wajsman Z; Marino R; Parsons J; Oblon D; McCarley D
Semin Urol; 1990 Aug; 8(3):210-5. PubMed ID: 2119051
[No Abstract] [Full Text] [Related]
[Next] [New Search]
